Piramal Pharma LimitedNSE: PPLPHARMA

Piramal Pharma Limited Press Release Jan 29 2026

· Issued by Piramal Pharma Limited via NSE India

Filed with NSE · · 28 pages · English

Summary by 6ix AI

The report highlights challenges such as inventory destocking and slower order inflows, but also notes early signs of recovery in the biopharma sector and increased customer interest in their facilities. Additionally, the company has made significant investments to expand its capabilities and has entered into an agreement to acquire a branded injectable product, Kenalog, to enhance its portfolio. Overall, despite a challenging year, the company remains optimistic about future growth prospects and is focused on strengthening its core business areas.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Piramal Pharma Limited on 6ix

In the deck

Earlier from Piramal Pharma

Later from Piramal Pharma

All Piramal Pharma news releases